When Medicine is Not Enough for Schizophrenia and Psychosis New York, June 30, 2022 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “When Medicine is Not Enough for Schizophrenia and Psychosis” on Tuesday,...

Cognitive Impairment in Psychosis: What it is and How it's Treated - A Free Webinar from the Brain & Behavior Research Foundation New York, July 08, 2021 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “Cognitive Impairment in Psychosis: What it is and How it's Treated” on...

AXIM Biotech Enters Clinical Study Agreement with University of British Columbia to Begin Clinical Trial On CBD Chewing Gum For Treatment of Drug-Related Psychosis NEW YORK, Aug. 02, 2017 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that it has entered into a...

AXIM Biotech Advisory Board Member Presented at CannMed 2017 Personalized Cannabinoid Medicine Conference at Harvard NEW YORK, April 13, 2017 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that Dr. Ilya Reznik, a...

Access to Cannabis Should Not Occur Prior to Age 21, according to a position statement by the Canadian Consortium for Early Intervention in Psychosis HAMILTON, Ontario, Feb. 02, 2017 (GLOBE NEWSWIRE) -- In response to the recommendations of the Task Force on Marijuana Legalization and Regulation, the Canadian Consortium for Early Intervention in...